CO4700522A1 - Quinazolinonas bisustituidas en 2, 8. - Google Patents
Quinazolinonas bisustituidas en 2, 8.Info
- Publication number
- CO4700522A1 CO4700522A1 CO96002168A CO96002168A CO4700522A1 CO 4700522 A1 CO4700522 A1 CO 4700522A1 CO 96002168 A CO96002168 A CO 96002168A CO 96002168 A CO96002168 A CO 96002168A CO 4700522 A1 CO4700522 A1 CO 4700522A1
- Authority
- CO
- Colombia
- Prior art keywords
- linear
- carbon atoms
- branched alkyl
- phenyl
- branched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Paints Or Removers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Quinazolinonas bisustituidas en 2,8, de fórmula general (I)en la cualA representa oxiranilo que, dado el caso, está sustituido por alquilo lineal o ramificado con hasta 8 átomos de carbono que, por su parte, puede estar sustituido por fenilo, o representa un resto de fórmulaen donde R1 significa hidrógeno o alquilo lineal o ramificado con hasta 6 átomos de carbono,R2 significa alquilo lineal o ramificado con hasta 8 átomos de carbono que, dado el caso, está sustituido por fenilo, R3 significa alquilo lineal o ramificado con hasta 5 átomos de carbono o un grupo de fórmula -OR6 ,en dondeR6 significa hidrógeno, un grupo protector de hidroxilo o alquilo, lineal o ramificado, con hasta 5 átomos de carbono,R4 significa alquilo lineal o ramificado con 2 a 10 átomos de carbono que, dado el caso, está sustituido por fenilo, L significa un resto de fórmula -CO-, -CH(OH), -CH2 , -CH(N3 ) ó -CH(OSO2 R7 ) en donde R7 significa alquilo lineal o ramificado con hasta 4 átomos de carbono o fenilo, R5 significa alquilo lineal o ramificado con 3 a 8 átomos de carbono que, dado el caso, está sustituido por fenilo, o significa bencilo o 2-feniletilo, D representa hidrógeno o un grupo de fórmula-SO2 -NR8 R9 , en donde R8 y R9 son iguales o distintos y significan hidrógeno, fenilo o alquilo lineal o ramificado con hasta hasta 6 átomos de carbono que, dado el caso, está sustituido por hidroxilo, o, junto con el átomo de nitrógeno, forman un heterociclo saturado de 5 a 6 eslabones con hasta otros 2 heteroátomos del grupo S, N y/u o que, dado el caso, está sustituido también sobre una función N libre por alquilo, lineal o ramificado, con hasta 6 átomos de carbono que, por su parte, puede estar sustituido por hidroxilo, E representa alquilo lineal o ramificado con hasta 8 átomos de carbono y sus tautómeros y sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19501481A DE19501481A1 (de) | 1995-01-19 | 1995-01-19 | 2,8-Disubstituierte Chinazolinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4700522A1 true CO4700522A1 (es) | 1998-12-29 |
Family
ID=7751829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO96002168A CO4700522A1 (es) | 1995-01-19 | 1996-01-19 | Quinazolinonas bisustituidas en 2, 8. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5721238A (es) |
| EP (1) | EP0722937A1 (es) |
| JP (1) | JPH08253457A (es) |
| KR (1) | KR960029325A (es) |
| CN (1) | CN1134417A (es) |
| AR (1) | AR006738A1 (es) |
| AU (1) | AU704102B2 (es) |
| BG (1) | BG100293A (es) |
| BR (1) | BR9600148A (es) |
| CA (1) | CA2167345A1 (es) |
| CO (1) | CO4700522A1 (es) |
| CZ (1) | CZ16796A3 (es) |
| DE (1) | DE19501481A1 (es) |
| EE (1) | EE9600019A (es) |
| FI (1) | FI960227A (es) |
| HR (1) | HRP960004A2 (es) |
| HU (1) | HUP9600114A3 (es) |
| IL (1) | IL116770A (es) |
| IN (1) | IN184956B (es) |
| MA (1) | MA23780A1 (es) |
| NO (1) | NO307513B1 (es) |
| NZ (1) | NZ280831A (es) |
| PE (1) | PE66696A1 (es) |
| PL (1) | PL312352A1 (es) |
| RO (1) | RO117451B1 (es) |
| RU (1) | RU2158733C2 (es) |
| SG (1) | SG34377A1 (es) |
| SK (1) | SK7796A3 (es) |
| SV (1) | SV1996000005A (es) |
| TR (1) | TR199600029A2 (es) |
| YU (1) | YU1496A (es) |
| ZA (1) | ZA96397B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| CA2238283C (en) | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| US20020025969A1 (en) * | 1997-07-09 | 2002-02-28 | Wolf-Georg Forssmann | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases |
| US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| US6187790B1 (en) | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| US6110489A (en) * | 1998-05-01 | 2000-08-29 | Cutler; Neal R. | Use of quinolines and quinolones to treat male erectile dysfunction |
| US6194433B1 (en) * | 1998-10-05 | 2001-02-27 | Neal R. Cutler | Sexual dysfunction in females |
| US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6132753A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6426084B1 (en) * | 2000-06-19 | 2002-07-30 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| US6303135B1 (en) | 1999-07-08 | 2001-10-16 | Neal R. Cutler | Use of quinolines and quinolones to treat male erectile dysfunction |
| US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
| US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
| EP1316316B1 (en) * | 2000-09-06 | 2012-04-04 | Mitsubishi Tanabe Pharma Corporation | Preparations for oral administration |
| US6562838B2 (en) * | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
| JP4179784B2 (ja) | 2001-02-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 口腔内速崩壊性錠 |
| HUP0500117A3 (en) * | 2001-11-30 | 2008-03-28 | Pfizer Prod Inc | Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| AU2003250701A1 (en) | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| CA2542007C (en) | 2002-10-09 | 2010-06-29 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| AU2003303460A1 (en) * | 2002-12-27 | 2004-07-22 | Tibotec Bvba | Fluorogenic enzyme substrates and methods of preparation |
| CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
| EP2079739A2 (en) * | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| EP2121681B1 (en) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| CN101429166B (zh) * | 2007-11-07 | 2013-08-21 | 上海特化医药科技有限公司 | 喹唑啉酮衍生物及其制备方法和用途 |
| WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| WO2010065751A2 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| JP6393037B2 (ja) | 2010-09-15 | 2018-09-19 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃアゴニストの製剤および使用方法 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| MX2016009663A (es) * | 2014-01-23 | 2016-11-17 | H Lee Moffitt Cancer Ct & Res | Derivados de icariina. |
| US10300042B2 (en) | 2014-06-23 | 2019-05-28 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
| CN110590769B (zh) * | 2019-06-13 | 2021-09-24 | 中山大学 | 一对喹唑啉酮生物碱对映体及其制备方法和应用 |
| WO2024026424A1 (en) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Quinazolinone derivatives as and related uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3169129A (en) * | 1963-05-10 | 1965-02-09 | American Cyanamid Co | 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones |
| US4431440A (en) * | 1981-02-20 | 1984-02-14 | American Cyanamid Company | Method to alter or control the development and/or the life cycle of various plant species |
| GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
-
1995
- 1995-01-19 DE DE19501481A patent/DE19501481A1/de not_active Withdrawn
- 1995-12-26 IN IN2408DE1995 patent/IN184956B/en unknown
-
1996
- 1996-01-05 HR HR19501481.2A patent/HRP960004A2/hr not_active Application Discontinuation
- 1996-01-08 EP EP96100154A patent/EP0722937A1/de not_active Withdrawn
- 1996-01-11 US US08/584,865 patent/US5721238A/en not_active Expired - Fee Related
- 1996-01-12 YU YU1496A patent/YU1496A/sh unknown
- 1996-01-15 TR TR96/00029A patent/TR199600029A2/xx unknown
- 1996-01-15 AU AU40980/96A patent/AU704102B2/en not_active Ceased
- 1996-01-16 CA CA002167345A patent/CA2167345A1/en not_active Abandoned
- 1996-01-16 NZ NZ280831A patent/NZ280831A/en unknown
- 1996-01-16 RO RO96-00077A patent/RO117451B1/ro unknown
- 1996-01-16 IL IL11677096A patent/IL116770A/xx active IP Right Grant
- 1996-01-17 JP JP8022973A patent/JPH08253457A/ja active Pending
- 1996-01-17 SG SG1996000263A patent/SG34377A1/en unknown
- 1996-01-17 FI FI960227A patent/FI960227A/fi unknown
- 1996-01-17 PL PL96312352A patent/PL312352A1/xx unknown
- 1996-01-18 EE EE9600019A patent/EE9600019A/xx unknown
- 1996-01-18 SK SK77-96A patent/SK7796A3/sk unknown
- 1996-01-18 BG BG100293A patent/BG100293A/xx unknown
- 1996-01-18 KR KR1019960001004A patent/KR960029325A/ko not_active Application Discontinuation
- 1996-01-18 RU RU96100854/04A patent/RU2158733C2/ru active
- 1996-01-18 CZ CZ96167A patent/CZ16796A3/cs unknown
- 1996-01-18 ZA ZA96397A patent/ZA96397B/xx unknown
- 1996-01-18 NO NO960222A patent/NO307513B1/no unknown
- 1996-01-18 MA MA24135A patent/MA23780A1/fr unknown
- 1996-01-18 BR BR9600148A patent/BR9600148A/pt active Search and Examination
- 1996-01-19 AR ARP960101087A patent/AR006738A1/es unknown
- 1996-01-19 SV SV1996000005A patent/SV1996000005A/es unknown
- 1996-01-19 CO CO96002168A patent/CO4700522A1/es unknown
- 1996-01-19 CN CN96101906A patent/CN1134417A/zh active Pending
- 1996-01-19 PE PE1996000044A patent/PE66696A1/es not_active Application Discontinuation
- 1996-01-19 HU HU9600114A patent/HUP9600114A3/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4700522A1 (es) | Quinazolinonas bisustituidas en 2, 8. | |
| ID29452A (id) | 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus | |
| CO4900062A1 (es) | Piridinas condensadas con heterociclos | |
| CO4770977A1 (es) | Derivados de purin-6-ona | |
| KR870006072A (ko) | 라파마이신 전구체의 제조방법 | |
| PE20001093A1 (es) | 3-amino-4-aril-maleimidas como inhibidores de gsk-3 | |
| MX12394A (es) | Procedimiento par la obtencion de carbamatos de polietilenglicol. | |
| CO4870759A1 (es) | Piridinas condensadas biciclicas | |
| CO5011045A1 (es) | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos | |
| CO4700523A1 (es) | Purin-6-onas bisustituidas en 2,9 | |
| DE69230379D1 (de) | 10-disacetoxytaxolderivate | |
| ES471797A1 (es) | Procedimiento para la preparacion de nuevos 1-ariloxi-2-hi- droxi-3 alcohilenaminopropanos, racemicos u opticamente ac- tivos | |
| FI952101A0 (fi) | Merkaptanfoerening | |
| DK0947504T3 (da) | 16-en-vitamin D-derivater | |
| ES2189736T3 (es) | Derivados de la benzamida y medicamentos que los contienen. | |
| CY1110038T1 (el) | 4-(διαρυλομεθυλ)-1- πιπεραζινυλ παραγωγα | |
| DK0599968T3 (da) | Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler | |
| ES459755A1 (es) | Procedimiento para preparar carbamatos de oximas de deriva- dos del acido isonitrosocianocetico. | |
| FI933064A (fi) | 2-amino-n(((4-(aminokarbonyl)pyrimidin-2-yl)amino)alkyl)pyrimidin-4-karboxamidderivat, deras framstaellning och terapeutiska anvaendning | |
| ATE30603T1 (de) | Korrosionsinhibitoren. | |
| CO4990931A1 (es) | Uso de trifenilmetil-1,2,3-triazoles | |
| ES2058126T3 (es) | Derivados de 4-desoxi-3''-demetoxi-3''-metilen desmicosina. | |
| KR920702364A (ko) | 신규 세팔로스포린계 화합물 | |
| FI821570L (fi) | Nya aminoalkylfuranderivat och foerfarande foer deras framstaellning | |
| KR890009944A (ko) | 세팔로스포린 유도체 |